Appendix 4D - Half Year Accounts - 31 December 2025
Filed with ASX · · 21 pages · English
1Restated to reflect a 15 for 1 share consolidation completed during the current financial half-year ended 31 December 2025. Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $3,021,202 (31 December 2024: $1,520,310). During the period, the Group had total other income of $
Story so far
Earlier from Patrys
- Appointment of Chief Executive Officer
- Appendix 4C - Quarterly - 31 December 2025
- Investor Presentation
- Completion of Acquisition and Board Appointments
- Pipeline Expanded with Proprietary Injectable Antipsychotic
Later from Patrys
- RLS-2201 Manufacturing and Regulatory Pathway Initiated
- Investor Presentation - Broker Meets Biotech
- $3.2 million Placement to Advance Clinical Trials
- Appendix 4C - Quarterly - 31 March 2026
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys